HeartFlow
HeartFlow is a commercial-stage medical technology company that pioneers the use of software and AI to deliver non-invasive solutions for diagnosing and managing coronary artery disease (CAD). The company's AI-powered platform uses coronary computed tomography angiography (CCTA) scans to create personalized 3D heart models, providing clinicians with critical diagnostic and prognostic information through three main components: Roadmap Analysis for anatomic narrowing visualization, FFRCT Analysis for blood flow assessment, and Plaque Analysis for coronary plaque characterization. HeartFlow is the global leader in AI technology for CAD management, having helped clinicians manage over 400,000 patients worldwide.
Public Company
HeartFlow is publicly traded
IPO'd on August 8, 2025
This company is no longer available on our private secondary market. Shares can be traded publicly under HTFL.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2007
Employees
501–1,000
Total Funding
$917.6M
4 rounds
Last Private Valuation
$6B
March 27, 2025
Funding
Total raised $917.6M across 4 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
IPO
Date
August 8, 2025
Amount
$316.67M
Valuation
$10B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| August 8, 2025 | IPO | $316.67M | $10B | Public market |
| March 27, 2025 | Series F-II | $98.4M | $6B | Not disclosed |
| April 6, 2023 | Series F | $215M | $3B | Bain Capital Life Sciences |
Funding by Round
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Valuation Trajectory
Valuation indexed to 1.0× at the selected entry round. Valuation marks are estimates and may contain errors. Hover each dot to compare.
Entry · Series E
$1.8B
Feb 2018
HeartFlow today
$10B
Aug 2025 · latest mark
HeartFlow multiple
5.6x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Prominent Investors
Leadership
John Farquhar
President and Chief Executive Officer
Charles A. Taylor
Founder and Chief Scientific Officer
John H. Stevens
Co-Founder and Chairman
Vikram Verghese
Chief Financial Officer
Stephanie Heller
Chief Human Resources Officer
Bill Weldon
Chairman of the Board
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Cleerly
AI-powered CCTA analysis platform founded in 2017 by cardiologist James Min, focusing on plaque quantification and long-term cardiovascular risk assessment
Elucid
AI-enabled cardiac imaging platform with FDA-approved CCTA analysis capabilities for coronary artery disease assessment
Caristo Diagnostics
Medical technology company developing AI-powered cardiovascular diagnostic solutions with FDA-approved CCTA analysis
Circle Cardiovascular Imaging
Cardiovascular imaging software company offering AI-enabled analysis tools for cardiac diagnostic imaging
Siemens Healthineers
Large medical technology conglomerate providing imaging and diagnostic solutions across multiple therapeutic areas including cardiology
Philips Healthcare
Major healthcare technology company offering medical imaging and diagnostic solutions for cardiovascular applications
HeartFlow Investment FAQ
HeartFlow FAQ
Yes, HeartFlow is publicly traded under the ticker symbol HTFL on the NASDAQ. The company went public in August 8, 2025.
HeartFlow trades under the ticker symbol HTFL on the NASDAQ. It began trading in August 8, 2025.
HeartFlow (HTFL on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker HTFL to place an order.
HeartFlow went public in August 8, 2025 via ipo, with an offering valuation of approximately $6B. HeartFlow completed its IPO on NASDAQ on August 8, 2025, under ticker symbol HTFL. The company priced 16.7M shares at $19.00 per share, raising approximately $316.7M in gross proceeds. With underwriters' option fully exercised, total shares sold reached 19.2M at the same price, generating approximately $364.2M. Shares opened at $28.00 on first day of trading, representing a 47.4% increase from the IPO price. The company achieved a market capitalization of $1.54B at IPO pricing and approximately $2.27B following the opening day trading surge.
HeartFlow raised $917.6M across 4 disclosed funding rounds prior to its public listing.
HeartFlow was co-founded by Charles A. Taylor, and John H. Stevens in 2007.
HeartFlow is headquartered in Redwood City, California, US.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.